Moderna and Merck Announce Promising Trial Results for Melanoma Vaccine Combination

Miami Fort Lauderdale, FL, August 20, 2026 —

Moderna and Merck Unveil Promising Melanoma Trial Data

Moderna and Merck have reported positive outcomes from a substantial clinical trial evaluating a combination therapy for melanoma patients. The experimental treatment pairs Moderna’s personalized mRNA cancer vaccine with Merck’s immunotherapy drug, Keytruda.

The trial focused on patients diagnosed with high-risk melanoma who had undergone surgical removal of the cancer. The primary objective of the combined treatment is to significantly reduce the likelihood of cancer recurrence and spread. Preliminary data suggests the therapy is achieving this goal, marking a potential advancement in the field of cancer immunotherapy.

Following these encouraging results, both companies are preparing to pursue regulatory approval for the treatment. Plans are in motion to submit applications to relevant health authorities within the coming months.

The development has already generated significant interest, contributing to a notable increase in Moderna’s stock price. This response underscores the market’s perception of the therapy’s potential impact.

Regarding safety, the trial did not reveal any novel safety concerns. The side effects observed were consistent with those previously documented for Keytruda and similar mRNA-based treatments. Commonly reported adverse events included fatigue and chills. Further details on the specific safety profile are expected as regulatory submissions progress.

This collaborative effort between Moderna and Merck represents a significant step forward in leveraging personalized medicine and immunotherapy to combat challenging forms of cancer like melanoma.

Story summarized from the original created by Rubén Rosario on wsvn.com, see more information here.

Media gallery